Efficacy of Magnesium Supplementation in Cancer Patients Developing Hypomagnesemia Due to Anti-EGFR Antibody: A Systematic Review
Kato T, Kawaguchi T, Funakoshi T, Fujiwara Y, Yasuda Y, Ando Y
Cancer diagnosis & prognosis · 4 citations
How it was studied
- Design
- Systematic review (classified by our AI screen)
- Studied in
- People
- Main outcome
- Health markers and function
Who paid for it
- Funding
- Independent funding
- University or hospital
- Nara Medical University
- University or hospital
- Kawasaki Medical School
Based on 2 listed funder(s).
Publication
- Published
- 2024-07-01 · Cancer Diagn Progn · vol. 4 · issue 4 · pp. 390–395
- Cited
- 4 citations · more than 50% of similar papers · 0.4× the field average
- References
- 23 works
- Access
- Free to read
- Research areas
- Magnesium in Health and Disease · Potassium and Related Disorders · Parathyroid Disorders and Treatments
- Keywords
- Hypomagnesemia, Medicine, Cetuximab, Internal medicine, Antibody, Cochrane Library, Cancer, Meta-analysis, Gastroenterology, Colorectal cancer, Magnesium, Immunology, Chemistry
6 authors
From JP
- Taigo KatoThe University of Osaka
- Takahisa KawaguchiKawasaki Municipal Hospital
- Taro FunakoshiKyoto University
- Yutaka FujiwaraAichi Cancer Center
- Yoshinari YasudaNagoya University
- Yuichi AndoNagoya University Hospital
Abstract
Background/aim
Hypomagnesemia is a common side effect of anti-epidermal growth factor receptor (EGFR) antibodies, which may lead to arrhythmia. However, there are no evidence-based guidelines for magnesium (Mg) supplementation in the management of hypomagnesemia in patients with anti-EGFR antibodies. Therefore, we performed a systematic review to address clinical questions regarding these cancer patients.
Materials and methods
Three electronic databases were searched for articles published until June 18, 2021. The main outcomes used were "anti-EGFR antibody" and "hypomagnesemia".
Results
After screening 78 references in PubMed, Cochrane Library, and ICHUSHI-web databases, three studies were included in the review. One study revealed the effectiveness of Mg supplementation in the management of hypomagnesemia in patients receiving cetuximab. However, no studies have investigated whether correcting hypomagnesemia can lead to the suppression of arrhythmias as a clinical outcome.
Conclusion
Weak evidence suggests that Mg supplementation, as a preventive measure when developing hypomagnesemia following the initiation of anti-EGFR antibody therapy, may prevent the worsening of hypomagnesemia, and subsequently prevent associated arrhythmia occurrence.
Abstract via Europe PMC. Copyright remains with the authors or publisher.
Community trust
Loading…
How much do you trust this study's findings?
Comments
Sign in to rate, comment on or flag this study.Sign inSomething wrong here?
Flag this study if its information, labels or funding look wrong. An editor reviews every flag.
Sign in to rate, comment on or flag this study.Sign inEducational information about published research. Not medical advice, and not a recommendation to start or stop anything.